NCT02307578

An Extended Access Program (EAP) for Perampanel

• Status: No Longer Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 1 Year
• Healthy volunteers: —

Summary

The main objective of this EAP is to ensure that participants participating in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401 continue to have access to perampanel until such time that the appropriate formulation of perampanel becomes commercially available in the country in which they reside or until no participants remain in the EAP.

Conditions

• Primary Generalized Tonic-Clonic or Partial Onset Seizures
• Lennox Gastaut Syndrome

Interventions

Type	Name	Description
DRUG	Perampanel	Perampanel will be available in 2-milligrams (mg), 4-mg and 8-mg tablets and as 0.5 milligram per milliliter (mg/mL) oral suspension. Participants will start this EAP with the dose that they were receiving at the end of their participation in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338 or EAP E2007-G000-401. Doses of perampanel can be adjusted based on clinical judgment.

Timeline

• First posted: 2014-12-04
• Last updated: 2025-09-15

Locations

27 sites across 10 countries: Belgium, Chile, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Serbia, Spain